Mesoblast (NASDAQ:MESO) Stock Price Up 3.4% – What’s Next?

Mesoblast Limited (NASDAQ:MESO) shot up 3.4% during mid-day trading on Tuesday . The company traded as high as $11.40 and last traded at $11.40. 454 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 750,209 shares. The stock had previously closed at $11.03.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MESO shares. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Mesoblast Stock Performance

The company’s 50 day moving average price is $9.06 and its two-hundred day moving average price is $7.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Hedge Funds Weigh In On Mesoblast

A number of large investors have recently made changes to their positions in MESO. GAMMA Investing LLC increased its position in shares of Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after purchasing an additional 1,663 shares in the last quarter. Signaturefd LLC raised its position in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the last quarter. Perkins Coie Trust Co purchased a new position in Mesoblast in the second quarter valued at about $68,000. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Mesoblast during the 2nd quarter worth approximately $80,000. Finally, Rathbones Group PLC purchased a new stake in shares of Mesoblast in the second quarter valued at $95,000. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.